Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | DRD5 | P21918 | 1/20 | 0.35 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6407106 | 1.00 | PNMT (0.37) | PNMTTDP1ADRA2ADRD5P2RY6 | |
| SCHEMBL6410811 | 0.84 | TDP1 (0.37) | TDP1FFAR4FFAR1PTGS2PTGS1 | |
| SCHEMBL6405425 | 0.84 | PTGS2 (0.44) | TDP1FFAR4PTGS2PTGS1 | |
| SCHEMBL6407885 | 0.84 | PTGS1 (0.44) | PNMTTDP1FFAR4FFAR1PTGS2 | |
| SCHEMBL6404285 | 0.84 | PTGS2 (0.44) | PNMTTDP1DRD5P2RY6AR | |
| SCHEMBL6410893 | 0.84 | GLS (0.38) | PNMTTDP1ADRA2AP2RY6AR | |
| SCHEMBL6406723 | 0.84 | PTGS2 (0.44) | PNMTTDP1DRD5P2RY6AR | |
| SCHEMBL6412199 | 0.84 | GLS (0.38) | PNMTTDP1ADRA2AP2RY6AR | |
| SCHEMBL6406365 | 0.84 | PTGS2 (0.44) | TDP1FFAR4PTGS2PTGS1 | |
| SCHEMBL6407208 | 0.84 | PTGS1 (0.44) | PNMTTDP1FFAR4FFAR1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951948-B2 | Method for synthesis of substituted azole libraries | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-20050010050-A1 | Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of COX-2-mediated disorders | G.D. SEARLE & CO. (US) | 2005-01-13 | — | — | US | disclosed |
| US-6822102-B2 | COMPOUNDS SUCH AS (2S,3R)-6,8-DICHLORO-3,4-DIHYDRO-2-(TRIFLUOROMETHYL)-2H-1-BENZOPYRAN-3 -CARBOXYLIC ACID, USED AS ANTIINFLAMMATORY, ANTIARTHRITIC, ANTICARCINOGENIC AGENTS OR ANALGESICS | PHARMACIA CORPORATION | 2004-11-23 | — | — | US | disclosed |
| EP-1274700-B1 | DIHYDROBENZOPYRANS, DIHYDROBENZOTHIOPYRANS, AND TETRAHYDROQUINOLINES FOR THE TREATMENT OF COX-2-MEDIATED DISORDERS | PHARMACIA CORP (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20030232844-A1 | Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2 mediated disorders | PHARMACIA CORPORATION | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050010050-A1 | Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of COX-2-mediated disorders | PTGS2, PTGES2, PTGER2 | PNMT 2278/4885TDP1 1920/4885ADRA2A 426/4885 |
| US-20030232844-A1 | Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2 mediated disorders | PTGS2, PTGS1, PTGES2 | PNMT 1854/4885TDP1 1068/4885ADRA2A 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.